Skip to main content Accessibility help
×
Home
  • Print publication year: 2016
  • Online publication date: December 2016

Chapter 7 - Neuropathology of dementia

Related content

Powered by UNSILO
1.Knopman, DS, Boeve, BF, Parisi, JE, Dickson, DW, Smith, GE, Ivnik, RJ, et al. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol. 2005;57(4):480–8.
2.Forman, MS, Farmer, J, Johnson, JK, Clark, CM, Arnold, SE, Coslett, HB, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59(6):952–62.
3.Seeley, W, Crawford, R, Zhou, J, Miller, B, Greicius, M. Neurodegenerative diseases target large-scale human brain networks. Neuron. 2009;62(1):4252.
4.Soto, C. Unfolding the role of protein misfolding in neurodegenerative diseases. Nat Rev Neurosci. 2003;4(1):4960.
5.Braak, H, Braak, E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathologica. 1991;82:239–59.
6.Braak, H, Ghebremedhin, E, Rub, U, Bratzke, H, Del Tredici, K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004;318(1):121–34.
7.Greicius, MD, Srivastava, G, Reiss, AL, Menon, V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci USA. 2004;101(13):4637–42.
8.Zhou, J, Gennatas, ED, Kramer, JH, Miller, BL, Seeley, WW. Predicting regional neurodegeneration from the healthy brain functional connectome. Neuron. 2012;73(6):1216–27.
9.Sanders, DW, Kaufman, SK, DeVos, SL, Sharma, AM, Mirbaha, H, Li, A, et al. Distinct tau prion strains propagate in cells and mice and define different tauopathies. Neuron. 2014;82(6):1271–88.
10.Ahmed, Z, Cooper, J, Murray, TK, Garn, K, McNaughton, E, Clarke, H, et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 2014;127(5):667–83.
11.de Calignon, A, Polydoro, M, Suarez-Calvet, M, William, C, Adamowicz, DH, Kopeikina, KJ, et al. Propagation of tau pathology in a model of early Alzheimer's disease. Neuron. 2012;73(4):685–97.
12.Volpicelli-Daley, LA, Luk, KC, Patel, TP, Tanik, SA, Riddle, DM, Stieber, A, et al. Exogenous alpha-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron. 2011;72(1):5771.
13.Clavaguera, F, Akatsu, H, Fraser, G, Crowther, RA, Frank, S, Hench, J, et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain. Proc Natl Acad Sci USA. 2013;110(23):9535–40.
14.Brun, A, Gustafson, L. Limbic lobe involvement in presenile dementia. Arch Psychiatr Nervenkr. 1978;226(2):7993.
15.Brun, A, Liu, X, Erikson, C. Synapse loss and gliosis in the molecular layer of the cerebral cortex in Alzheimer's disease and in frontal lobe degeneration. Neurodegeneration. 1995;4(2):171–7.
16.Weintraub, S, Mesulam, M-M. From neuronal networks to dementia: four clinical profiles. In: Foret, F, Christen, Y, Boller, F, eds. La Demence: Pourquoi? Paris: Foundation Nationale de Gerontologie; 1996. pp. 7597.
17.Saper, CB, Wainer, BH, German, DC. Axonal and transneuronal transport in the transmission of neurological disease: potential role in system degenerations, including Alzheimer's disease. Neuroscience. 1987;23(2):389–98.
18.Seeley, WW, Menon, V, Schatzberg, AF, Keller, J, Glover, GH, Kenna, H, et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci. 2007;27(9):2349–56.
19.Ritchie, K, Lovestone, S. The dementias. Lancet. 2002;360(9347):1759–66.
20.Hebert, LE, Scherr, PA, Bienias, JL, Bennett, DA, Evans, DA. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003;60(8):1119–22.
21.Kukull, WA, Higdon, R, Bowen, JD, McCormick, WC, Teri, L, Schellenberg, GD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol. 2002;59(11):1737–46.
22.Braak, H, Braak, E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging. 1995;16(3):271–84.
23.Hyman, BT, Damasio, AR. Hierarchical vulnerability of the entorhinal cortex and the hippocampal formation to Alzheimer neuropathological changes: a semiquantitative study. Neurology. 1990;40:403.
24.Hyman, BT, Damasio, AR, Van Hoesen, GW, Barnes, CL. Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984;298:8395.
25.Gorno-Tempini, ML, Dronkers, NF, Rankin, KP, Ogar, JM, Phengrasamy, L, Rosen, HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55(3):335–46.
26.Galton, CJ, Patterson, K, Xuereb, JH, Hodges, JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123 (Pt 3):484–98.
27.Chand, P, Grafman, J, Dickson, D, Ishizawa, K, Litvan, I. Alzheimer's disease presenting as corticobasal syndrome. Mov Disord. 2006;21(11):2018–22.
28.Lee, SE, Rabinovici, GD, Mayo, MC, Wilson, SM, Seeley, WW, DeArmond, SJ, et al. Clinicopathological correlations in corticobasal degeneration. Ann Neurol. 2011;70(2):327–40.
29.Zakzanis, KK, Boulos, MI. Posterior cortical atrophy. Neurologist. 2001;7(6):341–9.
30.Hof, PR, Vogt, BA, Bouras, C, Morrison, JH. Atypical form of Alzheimer's disease with prominent posterior cortical atrophy: a review of lesion distribution and circuit disconnection in cortical visual pathways. Vision Res. 1997;37(24):3609–25.
31.Johnson, J, Head, E, Kim, R, Starr, A, Cotman, C. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56(10):1233–9.
32.Lehmann, M, Madison, CM, Ghosh, PM, Seeley, WW, Mormino, E, Greicius, MD, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proc Natl Acad Sci USA. 2013;110(28):11606–11.
33.Pao, WC, Dickson, DW, Crook, JE, Finch, NA, Rademakers, R, Graff-Radford, NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord. 2011;25(4):364–8.
34.Crary, JF, Trojanowski, JQ, Schneider, JA, Abisambra, JF, Abner, EL, Alafuzoff, I, et al. Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol. 2014;128(6):755–66.
35.Brun, A, Gustafson, L. Distribution of cerebral degeneration in Alzheimer's disease. A clinico-pathological study. Arch Psychiatr Nervenkr. 1976;223(1):1533.
36.Alzheimer, A. Uber einen eigenartigen, schweren Erkrankungsprozess der Hirnrinde. Neurol Zbl. 1906;25:1134.
37.Dickson, DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol. 1997;56(4):321–39.
38.Goedert, M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993;16(11):460–5.
39.Arnold, SE, Hyman, BT, Flory, J, Damasio, AR, Van Hoesen, GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients in Alzheimer's disease. Cerebral Cortex. 1991;1(1):103–16.
40.Arriagada, PV, Growdon, JH, Hedley-Whyte, ET, Hyman, BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42(3 Pt 1):631–9.
41.Ball, MJ. Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol (Berl). 1977;37(2):111–18.
42.Vinters, HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2):311–24.
43.Gibson, PH, Tomlinson, BE. Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease. J Neurol Sci. 1977;33(1–2):199206.
44.Itagaki, S, McGeer, PL, Akiyama, H, Zhu, S, Selkoe, D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol. 1989;24(3):173–82.
45.McKeith, IG, Dickson, DW, Lowe, J, Emre, M, O'Brien, JT, Feldman, H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.
46.Uchikado, H, Lin, WL, DeLucia, MW, Dickson, DW. Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy. J Neuropathol Exp Neurol. 2006;65(7):685–97.
47.Amador-Ortiz, C, Lin, WL, Ahmed, Z, Personett, D, Davies, P, Duara, R, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61(5):435–45.
48.Mirra, S, Heyman, A, McKeel, D, Sumi, SM, Crain, BJ, Brownlee, LM, et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479–86.
49.Braak, H, Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
50.Hyman, BT, Trojanowski, JQ. Consensus recommendations for the postmortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol. 1997;56(10):1095–7.
51.Hyman, BT, Phelps, CH, Beach, TG, Bigio, EH, Cairns, NJ, Carrillo, MC, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):113.
52.Montine, TJ, Phelps, CH, Beach, TG, Bigio, EH, Cairns, NJ, Dickson, DW, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):111.
53.Braak, H, Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239–59.
54.Mirra, SS, Heyman, A, McKeel, D, Sumi, SM, Crain, BJ, Brownlee, LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology. 1991;41(4):479–86.
55.Thal, DR, Rüb, U, Orantes, M, Braak, H. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58(12):1791–800.
56.Selkoe, DJ. Alzheimer's disease. Cold Spring Harb Perspect Biol. 2011;3(7).
57.Hardy, JA, Higgins, GA. Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992;256(5054):184–5.
58.Goedert, M, Spillantini, MG, Cairns, NJ, Crowther, RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron. 1992;8(1):159–68.
59.Grudzien, A, Shaw, P, Weintraub, S, Bigio, E, Mash, DC, Mesulam, MM. Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging. 2007;28(3):327–35.
60.Braak, H, Thal, DR, Ghebremedhin, E, Del Tredici, K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J Neuropathol Exp Neurol. 2011;70(11):960–9.
61.Grinberg, LT, Rüb, U, Ferretti, RE, Nitrini, R, Farfel, JM, Polichiso, L, et al. The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? Neuropathol Appl Neurobiol. 2009;35(4):406–16.
62.Insausti, R, Amaral, DG, Cowan, WM. The entorhinal cortex of the monkey: III. Subcortical afferents. J Comp Neurol. 1987;264(3):396408.
63.Farrer, LA, Myers, RH, Cupples, LA, St George-Hyslop, PH, Bird, TD, Rossor, MN, et al. Transmission and age-at-onset patterns in familial Alzheimer's disease: evidence for heterogeneity. Neurology. 1990;40(3 Pt 1):395403.
64.St George-Hyslop, PH, Tanzi, RE, Polinsky, RJ. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science. 1987;235:885–90.
65.Schellenberg, GD, Bird, TD, Wijsman, EM. Genetic linkage evidence for a familial Alzheimer's disease locus on chromosome 14. Science. 1992;258:668–71.
66.Levy-Lahad, E, Wasco, W, Poorkaj, P, Romano, DM, Oshima, J, Pettingell, WH, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269(5226):973–7.
67.Schmitt, FA, Davis, DG, Wekstein, DR, Smith, CD, Ashford, JW, Markesbery, WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology. 2000;55(3):370–6.
68.Musiek, ES, Holtzman, DM. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement. Curr Op Neurol. 2012;25(6):715–20.
69.Polymeropoulos, M, Lavedan, C, Leroy, E. Mutation in the alpha-synuclein gene identified in families with Parkinson's diseae. Science. 1997;276:2045–8.
70.Soma, H, Yabe, I, Takei, A, Fujiki, N, Yanagihara, T, Sasaki, H. Heredity in multiple system atrophy. J Neurol Sci. 2006;240(1–2):107–10.
71.Hara, K, Momose, Y, Tokiguchi, S, Shimohata, M, Terajima, K, Onodera, O, et al. Multiplex families with multiple system atrophy. Arch Neurol. 2007;64(4):545–51.
72.McKeith, I, Galasko, D, Kosaka, K. Consensus guidleines for the clinical and pathologic diagnosis of dementia with Lewy bodies. Neurology. 1996;47:1113–24.
73.Holmes, C, Cairns, N, Lantos, P, Mann, A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia, and dementia with Lewy bodies. Br J Psychiatry. 1999;174:4551.
74.Lim, A, Tsuang, D, Kukull, W, Nochlin, D, Leverenz, J, McCormick, W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc. 1999;47(5):564–9.
75.Ransmayr, G. Dementia with Lewy bodies: prevalence, clinical spectrum and natural history. J Neural Transm Suppl. 2000(60):303–14.
76.McKeith, IG, Dickson, DW, Lowe, J, Emre, M, O'Brien, JT, Feldman, H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–72.
77.Double, KL, Halliday, GM, McRitchie, DA, Reid, WG, Hely, MA, Morris, JG. Regional brain atrophy in idiopathic parkinson's disease and diffuse Lewy body disease. Dementia. 1996;7(6):304–13.
78.Perry, RH, Irving, D, Blessed, G, Fairbairn, A, Perry, EK. Senile dementia of Lewy body type. A clinically and neuropathologically distinct form of Lewy body dementia in the elderly. J Neurol Sci. 1990;95:119–39.
79.Rezaie, P, Cairns, NJ, Chadwick, A, Lantos, PL. Lewy bodies are located preferentially in limbic areas in diffuse Lewy body disease. Neurosci Lett. 1996;212(2):111–14.
80.Gomez-Tortosa, E, Newell, K, Irizarry, MC, Albert, M, Growdon, JH, Hyman, BT. Clinical and quantitative pathologic correlates of dementia with Lewy bodies. Neurology. 1999;53(6):1284–91.
81.Giasson, B, M-Y Lee, V, Trojanowski, JQ. Parkinson's disease, dementia with Lewy bodies, multiple system atrophy and the spectrum of disease with alpha synuclein inclusions. Second edition. In Esiri, MM, M-Y Lee, V, Trojanowski, JQ, eds, The Neuropathology of Dementia. New York: Cambridge University Press; 2004. pp. 353–75.
82.Dickson, DW, Ruan, D, Crystal, H, Mark, MH, Davies, P, Kress, Y, et al. Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD. Neurology. 1991;41(9):1402–9.
83.Dickson, D, Schmidt, M, Lee, V. Immunoreactivity profile of hippocampal Ca2/3 neurites in diffuse Lewy body disease. Acta Neuropathologica. 1994;87:269–76.
84.Spillantini, MG, Crowther, RA, Jakes, R, Hasegawa, M, Goedert, M. Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA. 1998;95(11):6469–73.
85.Zaccai, J, Brayne, C, McKeith, I, Matthews, F, Ince, PG. MRC Cognitive Function AeNS. Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology. 2008;70(13):1042–8.
86.Braak, H, de Vos, RA, Bohl, J, Del Tredici, K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006;396(1):6772.
87.Gold, A, Turkalp, ZT, Munoz, DG. Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease. Mov Disord. 2013;28(2):237–40.
88.Kosaka, K. Diffuse Lewy body disease. Neuropathology. 2000;20 Suppl:S73–8.
89.Merdes, AR, Hansen, LA, Jeste, DV, Galasko, D, Hofstetter, CR, Ho, GJ, et al. Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology. 2003;60(10):1586–90.
90.Del Ser, T, Hachinski, V, Merskey, H, Munoz, DG. Clinical and pathologic features of two groups of patients with dementia with Lewy bodies: effect of coexisting Alzheimer-type lesion load. Alzheimer Dis Assoc Disord. 2001;15(1):3144.
91.Lopez, OL, Becker, JT, Kaufer, DI, Hamilton, RL, Sweet, RA, Klunk, W, et al. Research evaluation and prospective diagnosis of dementia with Lewy bodies. Arch Neurol. 2002;59(1):43–6.
92.Morra, LF, Donovick, PJ. Clinical presentation and differential diagnosis of dementia with Lewy bodies: a review. Int J Geriatr Psychiatry. 2014;29(6):569–76.
93.Schrag, A, Ben-Shlomo, Y, Quinn, NP. Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study. Lancet. 1999;354(9192):1771–5.
94.Wenning, GK, Colosimo, C, Geser, F, Poewe, W. Multiple system atrophy. Lancet Neurol. 2004;3(2):93103.
95.Wenning, GK, Tison, F, Ben Shlomo, Y, Daniel, SE, Quinn, NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. 1997;12(2):133–47.
96.Gilman, S, Low, PA, Quinn, N, Albanese, A, Ben-Shlomo, Y, Fowler, CJ, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. 1999;163(1):94–8.
97.Robbins, TW, James, M, Owen, AM, Lange, KW, Lees, AJ, Leigh, PN, et al. Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J Neurol Neurosurg Psychiatry. 1994;57(1):7988.
98.Meco, G, Gasparini, M, Doricchi, F. Attentional functions in multiple system atrophy and Parkinson's disease. J Neurol Neurosurg Psychiatry. 1996;60(4):393–8.
99.Burk, K, Daum, I, Rub, U. Cognitive function in multiple system atrophy of the cerebellar type. Mov Disord. 2006;21(6):772–6.
100.Gilman, S, Wenning, GK, Low, PA, Brooks, DJ, Mathias, CJ, Trojanowski, JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008;71(9):670–6.
101.Sato, K, Kaji, R, Matsumoto, S, Goto, S. Cell type-specific neuronal loss in the putamen of patients with multiple system atrophy. Mov Disord. 2007;22(5):738–42.
102.Wenning, GK, Tison, F, Elliott, L, Quinn, NP, Daniel, SE. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord. 1996;11(2):157–62.
103.Gai, WP, Power, JH, Blumbergs, PC, Blessing, WW. Multiple-system atrophy: a new alpha-synuclein disease? Lancet. 1998;352(9127):547–8.
104.Tu, PH, Galvin, JE, Baba, M, Giasson, B, Tomita, T, Leight, S, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol. 1998;44(3):415–22.
105.Lantos, PL. The definition of multiple system atrophy: a review of recent developments. J Neuropathol Exp Neurol. 1998;57(12):1099–111.
106.Duda, JE, Giasson, BI, Gur, TL, Montine, TJ, Robertson, D, Biaggioni, I, et al. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol. 2000;59(9):830–41.
107.Trojanowski, JQ, Revesz, T, MSA NWGo. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol. 2007;33(6):615–20.
108.Lin, WL, DeLucia, MW, Dickson, DW. Alpha-synuclein immunoreactivity in neuronal nuclear inclusions and neurites in multiple system atrophy. Neurosci Lett. 2004;354(2):99102.
109.Ratnavalli, E, Brayne, C, Dawson, K, Hodges, JR. The prevalence of frontotemporal dementia. Neurology. 2002;58(11):1615–21.
110.Knopman, DS, Petersen, RC, Edland, SD, Cha, RH, Rocca, WA. The incidence of frontotemporal lobar degeneration in Rochester, Minnesota, 1990 through 1994. Neurology. 2004;62(3):506–8.
111.Baborie, A, Griffiths, TD, Jaros, E, McKeith, IG, Burn, DJ, Richardson, A, et al. Pathological correlates of frontotemporal lobar degeneration in the elderly. Acta Neuropathol. 2011;121(3):365–71.
112.Mackenzie, I, Neumann, M, Bigio, E, Cairns, N, Alafuzoff, I, Kril, J, et al. Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol. 2010;119(1):14.
113.Neary, D, Snowden, JS, Gustafson, L, Passant, U, Stuss, D, Black, S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–54.
114.Gorno-Tempini, ML, Hillis, AE, Weintraub, S, Kertesz, A, Mendez, M, Cappa, SF, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006–14.
115.Rascovsky, K, Hodges, JR, Knopman, D, Mendez, MF, Kramer, JH, Neuhaus, J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456–77.
116.Schroeter, ML, Raczka, K, Neumann, J, von Cramon, DY. Neural networks in frontotemporal dementia – A meta-analysis. Neurobiol Aging. 2006;29(3):418–26.
117.Perry, RJ, Graham, A, Williams, G, Rosen, H, Erzinclioglu, S, Weiner, M, et al. Patterns of frontal lobe atrophy in frontotemporal dementia: a volumetric MRI study. Dement Geriatr Cogn Disord. 2006;22(4):278–87.
118.Seeley, WW, Crawford, R, Rascovsky, K, Kramer, JH, Weiner, M, Miller, BL, et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol. 2008;65(2):249–55.
119.Broe, M, Hodges, JR, Schofield, E, Shepherd, CE, Kril, JJ, Halliday, GM. Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology. 2003;60(6):1005–11.
120.Seeley, WW, Carlin, DA, Allman, JM, Macedo, MN, Bush, C, Miller, BL, et al. Early frontotemporal dementia targets neurons unique to apes and humans. Ann Neurol. 2006;60(6):660–7.
121.Kim, EJ, Sidhu, M, Gaus, SE, Huang, EJ, Hof, PR, Miller, BL, et al. Selective frontoinsular von Economo neuron and fork cell loss in early behavioral variant frontotemporal dementia. Cereb Cortex. 2012;22(2):251–9.
122.Santillo, AF, Englund, E. Greater loss of von Economo neurons than loss of layer II and III neurons in behavioral variant frontotemporal dementia. Am J Neurodegen Dis. 2014;3(2):6471.
123.Santillo, AF, Nilsson, C, Englund, E. von Economo neurones are selectively targeted in frontotemporal dementia. Neuropathol Appl Neurobiol. 2013;39(5):572–9.
124.Evrard, HC, Forro, T, Logothetis, NK. Von Economo neurons in the anterior insula of the macaque monkey. Neuron. 2012;74(3):482–9.
125.Hodges, JR, Patterson, K, Oxbury, S, Funnell, E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115 (Pt 6):1783–806.
126.Snowden, J. Semantic dementia. In O'Brien, J, Ames, D, Burns, A, eds, Dementia. Second edition. New York: Oxford University Press; 2000. pp. 769–78.
127.Seeley, WW, Bauer, AM, Miller, BL, Gorno-Tempini, ML, Kramer, JH, Weiner, M, et al. The natural history of temporal variant frontotemporal dementia. Neurology. 2005;64(8):1384–90.
128.Thompson, SA, Patterson, K, Hodges, JR. Left/right asymmetry of atrophy in semantic dementia: behavioral-cognitive implications. Neurology. 2003;61(9):1196–203.
129.Guo, CC, Gorno-Tempini, ML, Gesierich, B, Henry, M, Trujillo, A, Shany-Ur, T, et al. Anterior temporal lobe degeneration produces widespread network-driven dysfunction. Brain. 2013;136(Pt 10):2979–91.
130.Josephs, KA, Duffy, JR, Strand, EA, Whitwell, JL, Layton, KF, Parisi, JE, et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain. 2006;129(Pt 6):1385–98.
131.Neary, D, Snowden, JS, Mann, DM, Northen, B, Goulding, PJ, Macdermott, N. Frontal lobe dementia and motor neuron disease. J Neurol Neurosurg Psychiatry. 1990;53(1):2332.
132.Boxer, AL, Geschwind, MD, Belfor, N, Gorno-Tempini, ML, Schauer, GF, Miller, BL, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol. 2006;63(1):81–6.
133.Steele, JC, Richardson, JC, Olszewski, J. Progressive supranuclear palsy. Arch Neurol. 1964;10(April):333–60.
134.Gardner, RC, Boxer, AL, Trujillo, A, Mirsky, JB, Guo, CC, Gennatas, ED, et al. Intrinsic connectivity network disruption in progressive supranuclear palsy. Ann Neurol. 2013;73(5):603–16.
135.Braak, H, Del Tredici, K, Rüb, U, de Vos, R, Jansen Steur, E, Braak, E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197211.
136.Miki, Y, Mori, F, Tanji, K, Kurotaki, H, Kakita, A, Takahashi, H, et al. An autopsy case of incipient Pick's disease: immunohistochemical profile of early-stage Pick body formation. Neuropathology. 2014;34(4):386–91.
137.Mahoney, CJ, Beck, J, Rohrer, JD, Lashley, T, Mok, K, Shakespeare, T, et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain. 2012;135(Pt 3):736–50.
138.Lee, SE, Khazenzon, AM, Trujillo, AJ, Guo, CC, Yokoyama, JS, Sha, SJ, et al. Altered network connectivity in frontotemporal dementia with C9ORF72 hexanucleotide repeat expansion. Brain. 2014;137(Pt 11):3047–60.
139.Munoz, DG, Dickson, DW, Bergeron, C, Mackenzie, IR, Delacourte, A, Zhukareva, V. The neuropathology and biochemistry of frontotemporal dementia. Ann Neurol. 2003;54 Suppl 5:S24–8.
140.Dickson, DW. Pick's disease: a modern approach. Brain Pathol. 1998;8(2):339–54.
141.Probst, A, Tolnay, M, Langui, D, Goedert, M, Spillantini, MG. Pick's disease: hyperphosphorylated tau protein segregates to the somatoaxonal compartment. Acta Neuropathol (Berl). 1996;92(6):588–96.
142.Feany, MB, Mattiace, LA, Dickson, DW. Neuropathologic overlap of progressive supranuclear palsy, Pick's disease and corticobasal degeneration. J Neuropathol Exp Neurol. 1996;55(1):5367.
143.Feany, MB, Dickson, DW. Widespread cytoskeletal pathology characterizes corticobasal degeneration. Am J Pathol. 1995;146(6):1388–96.
144.Lantos, PL. The neuropathology of progressive supranuclear palsy. J Neural Transm Suppl. 1994;42:137–52.
145.Komori, T, Arai, N, Oda, M, Nakayama, H, Mori, H, Yagishita, S, et al. Astrocytic plaques and tufts of abnormal fibers do not coexist in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol (Berl). 1998;96(4):401–8.
146.Houlden, H, Baker, M, Morris, HR, MacDonald, N, Pickering-Brown, S, Adamson, J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology. 2001;56(12):1702–6.
147.Wilhelmsen, K, Lynch, T, Pavlou, E. Localization of disinhibition-dementia-parkinsonism-amyotrophy complex to 17q21-22. Am J Hum Gen. 1994;6:1159–65.
148.Foster, NL, Wilhelmsen, K, Sima, AA, Jones, MZ, D'Amato, CJ, Gilman, S. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Conference participants. Ann Neurol. 1997;41(6):706–15.
149.Bird, TD, Wijsman, EM, Nochlin, D, Leehey, M, Sumi, SM, Payami, H, et al. Chromosome 17 and hereditary dementia: linkage studies in three non-Alzheimer families and kindreds with late-onset FAD. Neurology. 1997;48(4):949–54.
150.Heutink, P, Stevens, M, Rizzu, P, Bakker, E, Kros, JM, Tibben, A, et al. Hereditary frontotemporal dementia is linked to chromosome 17q21-q22: a genetic and clinicopathological study of three Dutch families. Ann Neurol. 1997;41(2):150–9.
151.McKee, AC, Stern, RA, Nowinski, CJ, Stein, TD, Alvarez, VE, Daneshvar, DH, et al. The spectrum of disease in chronic traumatic encephalopathy. Brain. 2013;136(Pt 1):4364.
152.Bigio, EH, Lipton, AM, Yen, SH, Hutton, ML, Baker, M, Nacharaju, P, et al. Frontal lobe dementia with novel tauopathy: sporadic multiple system tauopathy with dementia. J Neuropathol Exp Neurol. 2001;60(4):328–41.
153.Ferrer, I, Santpere, G, van Leeuwen, FW. Argyrophilic grain disease. Brain. 2008;131(Pt 6):1416–32.
154.Grinberg, LT, Wang, X, Wang, C, Sohn, PD, Theofilas, P, Sidhu, M, et al. Argyrophilic grain disease differs from other tauopathies by lacking tau acetylation. Acta Neuropathol. 2013;125(4):581–93.
155.Ahmed, Z, Bigio, EH, Budka, H, Dickson, DW, Ferrer, I, Ghetti, B, et al. Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathol. 2013;126(4):537–44.
156.Neumann, M, Sampathu, DM, Kwong, LK, Truax, AC, Micsenyi, MC, Chou, TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130–3.
157.Arai, T, Hasegawa, M, Akiyama, H, Ikeda, K, Nonaka, T, Mori, H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–11.
158.Davidson, Y, Kelley, T, Mackenzie, IR, Pickering-Brown, S, Du Plessis, D, Neary, D, et al. Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathol (Berl). 2007;113(5):521–33.
159.Mackenzie, IR, Neumann, M, Baborie, A, Sampathu, DM, Du Plessis, D, Jaros, E, et al. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122(1):111–13.
160.Sampathu, D, Neumann, M, Kwong, L, Chou, T, Micsenyi, M, Truax, A, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169(4):1343–52.
161.Mackenzie, IR, Baborie, A, Pickering-Brown, S, Du Plessis, D, Jaros, E, Perry, RH, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 2006;112(5):539–49.
162.Baker, M, Mackenzie, IR, Pickering-Brown, SM, Gass, J, Rademakers, R, Lindholm, C, et al. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature. 2006;442(7105):916–19.
163.Cruts, M, Gijselinck, I, van der Zee, J, Engelborghs, S, Wils, H, Pirici, D, et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal dementia linked to chromosome 17q21. Nature. 2006;442(7105):920–4.
164.Mukherjee, O, Pastor, P, Cairns, NJ, Chakraverty, S, Kauwe, JS, Shears, S, et al. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol. 2006;60(3):314–22.
165.Schymick, JC, Yang, Y, Andersen, PM, Vonsattel, JP, Greenway, M, Momeni, P, et al. Progranulin mutations and amyotrophic lateral sclerosis or amyotrophic lateral sclerosis-frontotemporal dementia phenotypes. J Neurol Neurosurg Psychiatry. 2007;78(7):754–6.
166.Gass, J, Cannon, A, Mackenzie, IR, Boeve, B, Baker, M, Adamson, J, et al. Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Hum Mol Genet. 2006;15(20):29883001.
167.Barmada, SJ, Finkbeiner, S. Pathogenic TARDBP mutations in amyotrophic lateral sclerosis and frontotemporal dementia: disease-associated pathways. Rev Neurosci. 2010;21(4):251–72.
168.Borroni, B, Bonvicini, C, Alberici, A, Buratti, E, Agosti, C, Archetti, S, et al. Mutation within TARDBP leads to frontotemporal dementia without motor neuron disease. Hum Mutat. 2009;30(11):e974–83.
169.Borghero, G, Floris, G, Cannas, A, Marrosu, MG, Murru, MR, Costantino, E, et al. A patient carrying a homozygous p.A382T TARDBP missense mutation shows a syndrome including ALS, extrapyramidal symptoms, and FTD. Neurobiol Aging. 2011;32(12):2327.e1–5.
170.DeJesus-Hernandez, M, Mackenzie, IR, Boeve, BF, Boxer, AL, Baker, M, Rutherford, NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245–56.
171.Renton, AE, Majounie, E, Waite, A, Simón-Sánchez, J, Rollinson, S, Gibbs, JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257–68.
172.Simón-Sánchez, J, Dopper, EG, Cohn-Hokke, PE, Hukema, RK, Nicolaou, N, Seelaar, H, et al. The clinical and pathological phenotype of C9ORF72 hexanucleotide repeat expansions. Brain. 2012;135(Pt 3):723–35.
173.Donnelly, CJ, Zhang, PW, Pham, JT, Haeusler, AR, Mistry, NA, Vidensky, S, et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by anti-sense intervention. Neuron. 2013;80(2):415–28.
174.Lee, YB, Chen, HJ, Peres, JN, Gomez-Deza, J, Attig, J, Stalekar, M, et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Reports. 2013;5(5):1178–86.
175.Mori, K, Lammich, S, Mackenzie, IR, Forne, I, Zilow, S, Kretzschmar, H, et al. hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9ORF72 mutations. Acta Neuropathol. 2013;125(3):413–23.
176.Sareen, D, O'Rourke, JG, Meera, P, Muhammad, AK, Grant, S, Simpkinson, M, et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Science Translational Medicine. 2013;5(208):208ra149.
177.Su, Z, Zhang, Y, Gendron, TF, Bauer, PO, Chew, J, Yang, WY, et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. Neuron. 2014;83(5):1043–50.
178.Kwiatkowski, TJ, Bosco, DA, Leclerc, AL, Tamrazian, E, Vanderburg, CR, Russ, C, et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323(5918):1205–8.
179.Vance, C, Rogelj, B, Hortobágyi, T, De Vos, KJ, Nishimura, AL, Sreedharan, J, et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323(5918):1208–11.
180.Fujii, R, Takumi, T. TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci. 2005;118(Pt 24):5755–65.
181.Neumann, M, Rademakers, R, Roeber, S, Baker, M, Kretzschmar, H, Mackenzie, I. A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132(Pt 11):2922–31.
182.Neumann, M, Roeber, S, Kretzschmar, HA, Rademakers, R, Baker, M, Mackenzie, IR. Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathol. 2009;118(5):605–16.
183.Munoz, DG, Neumann, M, Kusaka, H, Yokota, O, Ishihara, K, Terada, S, et al. FUS pathology in basophilic inclusion body disease. Acta Neuropathol. 2009;118(5):617–27.
184.Roeber, S, Mackenzie, IR, Kretzschmar, HA, Neumann, M. TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathol. 2008;116(2):147–57.
185.Cairns, NJ, Zhukareva, V, Uryu, K, Zhang, B, Bigio, E, Mackenzie, IR, et al. Alpha-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol. 2004;164(6):2153–61.
186.Cairns, NJ, Grossman, M, Arnold, SE, Burn, DJ, Jaros, E, Perry, RH, et al. Clinical and neuropathologic variation in neuronal intermediate filament inclusion disease. Neurology. 2004;63(8):1376–84.
187.Josephs, KA, Uchikado, H, McComb, RD, Bashir, R, Wszolek, Z, Swanson, J, et al. Extending the clinicopathological spectrum of neurofilament inclusion disease. Acta Neuropathol. 2005;109(4):427–32.
188.Mackenzie, IR, Neumann, M. FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Res. 2012;1462:40–3.
189.Holm, IE, Englund, E, Mackenzie, IR, Johannsen, P, Isaacs, AM. A reassessment of the neuropathology of frontotemporal dementia linked to chromosome 3. J Neuropathol Exp Neurol. 2007;66(10):884–91.
190.Hodges, JR, Davies, RR, Xuereb, JH, Casey, B, Broe, M, Bak, TH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol. 2004;56(3):399406.
191.Knibb, JA, Xuereb, JH, Patterson, K, Hodges, JR. Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59(1):156–65.
192.Davies, RR, Hodges, JR, Kril, JJ, Patterson, K, Halliday, GM, Xuereb, JH. The pathological basis of semantic dementia. Brain. 2005;128(Pt 9):1984–95.
193.Gorno-Tempini, ML, Murray, RC, Rankin, KP, Weiner, MW, Miller, BL. Clinical, cognitive and anatomical evolution from nonfluent progressive aphasia to corticobasal syndrome: a case report. Neurocase. 2004;10(6):426–36.
194.Caso, F, Mandelli, ML, Henry, M, Gesierich, B, Bettcher, BM, Ogar, J, et al. In vivo signatures of nonfluent/agrammatic primary progressive aphasia caused by FTLD pathology. Neurology. 2014;82(3):239–47.
195.Hassan, A, Whitwell, JL, Josephs, KA. The corticobasal syndrome-Alzheimer's disease conundrum. Expert Rev Neurother. 2011;11(11):1569–78.
196.Shelley, BP, Hodges, JR, Kipps, CM, Xuereb, JH, Bak, TH. Is the pathology of corticobasal syndrome predictable in life? Mov Disord. 2009;24(11):1593–9.
197.Williams, DR, Holton, JL, Strand, C, Pittman, A, de Silva, R, Lees, AJ, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain. 2007;130(Pt 6):1566–76.
198.Folstein, S. Huntington's Disease: A Disorder of Families. Baltimore: Johns Hopkins University Press; 1989.
199.Feigin, A, Kieburtz, K, Bordwell, K, Como, P, Steinberg, K, Sotack, J, et al. Functional decline in Huntington's disease. Mov Disord. 1995;10(2):211–14.
200.Zakzanis, KK. The subcortical dementia of Huntington's disease. J Clin Exp Neuropsychol. 1998;20(4):565–78.
201.Mendez, MF. Huntington's disease: update and review of neuropsychiatric aspects. Int J Psychiatry Med. 1994;24(3):189208.
202.Berrios, GE, Wagle, AC, Markova, IS, Wagle, SA, Rosser, A, Hodges, JR. Psychiatric symptoms in neurologically asymptomatic Huntington's disease gene carriers: a comparison with gene negative at risk subjects. Acta Psychiatr Scand. 2002;105(3):224–30.
203.Vonsattel, JP, DiFiglia, M. Huntington disease. J Neuropathol Exp Neurol. 1998;57(5):369–84.
204.Graveland, GA, Williams, RS, DiFiglia, M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science. 1985;227(4688):770–3.
205.Vonsattel, J-P, Myers, RH, Stevens, TJ, Ferrante, RJ, Bird, ED, Richardson, EP. Neuropathological classification of Huntington's disease. J Neuropath Exp Neurol. 1985;44:559–77.
206.The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971–83.
207.Andrew, SE, Goldberg, YP, Kremer, B, Telenius, H, Theilmann, J, Adam, S, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet. 1993;4(4):398403.
208.Duyao, M, Ambrose, C, Myers, R, Novelletto, A, Persichetti, F, Frontali, M, et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet. 1993;4(4):387–92.
209.Rubinsztein, DC, Barton, DE, Davison, BC, Ferguson-Smith, MA. Analysis of the huntingtin gene reveals a trinucleotide-length polymorphism in the region of the gene that contains two CCG-rich stretches and a correlation between decreased age of onset of Huntington's disease and CAG repeat number. Hum Mol Genet. 1993;2(10):1713–15.
210.Snell, RG, MacMillan, JC, Cheadle, JP, Fenton, I, Lazarou, LP, Davies, P, et al. Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet. 1993;4(4):393–7.
211.Li, SH, Schilling, G, Young, WS 3rd, Li, XJ, Margolis, RL, Stine, OC, et al. Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron. 1993;11(5):985–93.
212.Strong, TV, Tagle, DA, Valdes, JM, Elmer, LW, Boehm, K, Swaroop, M, et al. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nat Genet. 1993;5(3):259–65.
213.Bhide, PG, Day, M, Sapp, E, Schwarz, C, Sheth, A, Kim, J, et al. Expression of normal and mutant huntingtin in the developing brain. J Neurosci. 1996;16(17):5523–35.
214.Duyao, MP, Auerbach, AB, Ryan, A, Persichetti, F, Barnes, GT, McNeil, SM, et al. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science. 1995;269(5222):407–10.
215.Zuccato, C, Ciammola, A, Rigamonti, D, Leavitt, BR, Goffredo, D, Conti, L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001;293(5529):493–8.
216.Gauthier, LR, Charrin, BC, Borrell-Pages, M, Dompierre, JP, Rangone, H, Cordelieres, FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell. 2004;118(1):127–38.
217.DiFiglia, M, Sapp, E, Chase, KO, Davies, SW, Bates, GP, Vonsattel, JP, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997;277(5334):1990–3.
218.Gutekunst, CA, Li, SH, Yi, H, Mulroy, JS, Kuemmerle, S, Jones, R, et al. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci. 1999;19(7):2522–34.
219.Puoti, G, Bizzi, A, Forloni, G, Safar, JG, Tagliavini, F, Gambetti, P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11(7):618–28.
220.Cyngiser, TA. Creutzfeldt-Jakob disease: a disease overview. Am J Electroneurodiagnostic Technol. 2008;48(3):199208.
221.Zerr, I, Kallenberg, K, Summers, DM, Romero, C, Taratuto, A, Heinemann, U, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(Pt 10):2659–68.
222.Vitali, P, Maccagnano, E, Caverzasi, E, Henry, RG, Haman, A, Torres-Chae, C, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76(20):1711–19.
223.Johnson, RT. Prion diseases. Lancet Neurol. 2005;4(10):635–42.
224.Venneti, S. Prion diseases. Clin Lab Med. 2010;30(1):293309.
225.Ironside, JW. Variant Creutzfeldt-Jakob disease. Haemophilia. 2010;16 (Suppl 5):175–80.
226.Liberski, PP, Brown, P. Kuru – fifty years later. Neurol Neurochir Pol. 2007;41(6):548–56.
227.Budka, H, Aguzzi, A, Brown, P, Brucher, JM, Bugiani, O, Gullotta, F, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol. 1995;5(4):459–66.
228.Parchi, P, Strammiello, R, Giese, A, Kretzschmar, H. Phenotypic variability of sporadic human prion disease and its molecular basis: past, present, and future. Acta Neuropathol. 2011;121(1):91112.
229.Ironside, JW, McCardle, L, Horsburgh, A, Lim, Z, Head, MW. Pathological diagnosis of variant Creutzfeldt-Jakob disease. APMIS. 2002;110(1):7987.
230.Satoh, K, Muramoto, T, Tanaka, T, Kitamoto, N, Ironside, JW, Nagashima, K, et al. Association of an 11–12 kDa protease-resistant prion protein fragment with subtypes of dura graft-associated Creutzfeldt-Jakob disease and other prion diseases. J Gen Virol. 2003;84(Pt 10):2885–93.